The BVA-100 (Blood Volume Analyzer) is a revolutionary instrument, developed by DAXOR Corporation and approved by the FDA, to precisely measure blood volume in the human body.

Read More

Key Features

  • Superior  blood volume measurement
  • Results in under 1 hour
  • Clinically proven — significant survival benefits

Latest News

Daxor Receives Two Patents, One for Measurement of Total Body Albumin and a Second Patent for Improved Accuracy of Blood Volume Measurement

Daxor has received approval from the US Patent Office for a Total Body Albumin Analyzer, US Patent # 9,002,656. The patent for the total body albumin analyzer is the first one issued for an instrument to measure the total albumin within the human body.  Albumin is the major carrier molecule in the human body for […]

Read More

Daxor Receives Notification of Patent Approval and Issues an Update on its Stock Buyback Program

Daxor Corporation (NYSE MKT: DXR), a medical instrumentation and biotechnology company, announced the approval of a patent and an update on its stock buyback program. Daxor has received notification from the U.S. Patent Office that its patents for the total body albumin analyzer and its supplementary patent on its Blood Volume Analyzer filed on October […]

Read More


“BVA allows physicians to determine an accurate status on heart failure patients.”

Shamsuddin Khwaja
Cardiothoracic Surgeon
Fresno Heart and Surgical Hospital

“We are excited to have acquired the blood volume analyzer. We see this as a valuable tool for guiding therapy for our heart failure patients.”

Dr. Gamal Sidarous, Nuclear Medicine Physician at Banner Good Samaritan Medical Center 

“I view this as an opportunity to improve patient outcomes for those associated with poor prognosis.  I believe that this advanced testing method will become an essential service in treating heart failure and other life threatening conditions.”

Max Akin, president of North Alabama RadioPharmacy